Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations

October 14th 2025

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma

October 14th 2025

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer

October 13th 2025

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

Ficerafusp Alfa Earns FDA Breakthrough Therapy Designation for HPV-Negative, Recurrent/Metastatic HNSCC

October 13th 2025

The FDA granted breakthrough therapy designation to ficerafusp alfa plus pembrolizumab for metastatic/recurrent head and neck squamous cell carcinoma.

Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

October 13th 2025

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

Five Under 5: Top Oncology Videos for the Week of 10/5

October 12th 2025

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology

October 12th 2025

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab in solid tumors.

The OncFive: Top Oncology Articles for the Week of 10/5

October 11th 2025

The FDA approved adjuvant cemiplimab in cutaneous squamous cell carcinoma, issued a CRL to dasatinib in chronic myeloid leukemia, and more.

Perioperative Serplulimab Meets Primary End Point of EFS in Gastric Cancer

October 11th 2025

Perioperative serplulimab plus chemotherapy significantly prolonged EFS vs placebo plus chemotherapy in gastric cancer.

RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 10th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights renal cell carcinoma.

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 9th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 8th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in urothelial cancer.

Lung Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 6th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in lung cancer.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025

October 3rd 2025

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

OncLive’s September Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 3rd 2025

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

How AI-Driven Platforms Can Transform Clinical Trial Efficiency in Cancer Care

October 1st 2025

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

AI Offers Multitude of Benefits in Community Practice, But Barriers to Implementation Remain

September 29th 2025

Kashyap Patel MD, ABIM, BCMAS, discusses the present challenges with integrating AI tools into community practice.